티앤알바이오팹

246710KOSDAQ기초 의약물질 제조업

48.3 / 100

Reference Date: 2026-06-10

Financial Score13.0 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 26.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

T&N Biofabrication focuses on regenerative medicine, bio-surgical solutions, and cosmetics, leveraging its 3D bioprinting systems, bioinks, and biodegradable scaffolds. The company is developing 3D organoids and cell therapies through long-term R&D while also advancing short-term revenue streams via bio-surgical solutions.

Number of Employees

82people

Average Salary

51.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

4.22Industry Average 1.740.0Point

2.4x industry avg (risky)

ROE

-147.79Industry Average -6.033.5Point

24.5x industry avg (excellent)

Debt Ratio

228.72Industry Average 6.620.0Point

34.5x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲223.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -71.2% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
美·EU 동물실험 퇴출 본격화… K바이오에 기회 찾아온다
글로벌 규제 변화로 인해 티앤알바이오팹과 같은 비동물 시험 기술 기업의 성장 기회가 확대될 것으로 예상됩니다.
Positive
티앤알바이오팹, 1분기 매출 87억…전년대비 46%↑
티앤알바이오팹의 1분기 매출이 전년 동기 대비 46% 증가하며 실적 개선을 보여주고 있다.
Positive
티앤알바이오팹, ‘AI 바이오잉크 플랫폼 개발’ 국책과제 선정
티앤알바이오팹이 AI 기반 바이오잉크 플랫폼 개발 국책과제에 선정되어 기술 혁신과 성장 기대감이 높아졌다.

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 2,045Won52-week high 4,53552-week low 1,194

1-month return0.0Point

1m -26.70% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral분기보고서 (2026.03)2026-05-26